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HPV infection is common and may cause cancer among men who have sex with men
(MSM). Anal HPV infection (HPV+) was found in 85% of HIV-positive (HIV+) and 59% of
HIV-negative (HIV-) MSM in Bangkok, central Thailand. As little is known about HPV in this
group in northern Thailand, we studied MSM subgroups comprised of gay men (GM), bisex-
ual men (BM), and transgender women (TGW).
Methods
From July 2012 through January 2013, 85 (42.5% of 200) GM, 30 (15%) BM, and 85
(42.5%) TGWwho practiced receptive anal intercourse were recruited after informed con-
sent, followed by self-assisted computer interview, HIV testing, and anal swabs for
HPV genotyping.
Results
Of 197 adequate specimens, the overall prevalence of any HPV was 157 (80%). Prevalence
was 89% (76/85) in GM, 48% (14/29) in BM, and 81% (67/83) in TGW. The most common
high-risk types were HPV16 (27% of 197), HPV58 (23%), and HPV51 (18%). Prevalence of
high-risk types was 74% in 85 GM, 35% in 29 BM, and 71% in 83 TGW. Prevalence of any
HPV type, or high-risk type, was 100% and 94%, respectively, among 48 HIV+ MSM, 70%
and 54% among 120 HIV- MSM. Of the 197 specimens, 36% (70) had HPV types 16 and/or
18 in the bivalent vaccine, compared to 48% (95) with1 of types 16/18/06/11 in the quadri-
valent, 56% (111) for 16/18/31/33/45/52/58 in the 7-valent, and 64% (126) for 16/18/31/33/
45/52/58/06/11 in the 9-valent. HIV+, GM, and TGWwere independently associated with
HPV infection.
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Conclusions
We found higher rates of both any HPV and high-risk types than previous studies. Among
the heretofore unstudied TGW, their equivalent HPV rates were comparable to GM. Current
and investigational HPV vaccines could substantially protect GM, BM, and TGW from the
serious consequences of HPV infection especially among HIV + MSM.
Introduction
Human Papillomaviruses (HPV) are a group of DNA viruses commonly transmitted by sexual
activity or other direct contact. They can infect the genital and anorectal areas, mouth, and
throat of males and females.[1, 2] Over 40 types of HPV are reported, of which at least 13 are
considered high-risk for leading to neoplasia in infected body sites. HPV infection is well-
known for its association with the development of cervical cancer in women. To prevent this,
HPV vaccination has been implemented for young women in many industrialized countries.
[1, 3] There is also growing concern about the role of HPV in the increasing frequency of anal
cancer in men who have sex with men (MSM) in developed countries. [4–6]
In Thailand, sex between men is common, with data from integrated analysis and advocacy
across all surveys estimating that 2–15% of anatomical males have a history of sex with men.
[7] There are many categories of gender roles, gender identities, sexual orientations, and behav-
iors within the broad classification referred to as MSM in Thailand. In general, they are com-
prised of three sub groups: gay men (GM) who self-identify as men and prefer insertive and/or
receptive anal sex with other men, bisexual men (BM) who self-identify as men and engage in
insertive and/or receptive anal sex with men and women, and transgender women (TGW) who
are born as anatomical males (and who may or may not have undergone genital surgery), but
who self-identify as women and prefer receptive anal sex with men.[8–10] These groups have
different sexual practices that may pose different risks for acquisition of sexually transmitted
infections (STIs), especially for HPV.
The prevalence of different infecting HPV types appears to vary both geographically and
temporally. In 1990s, one HPV study among MSM in the USA reported the most common
high-risk HPV types were 16, 18, 31 and 53 in descending frequency without any HPV vaccina-
tion available during that time. [11] A study of MSM in China reported in 2010 revealed that
HPV type 16 was also the most frequent, followed by types 58 and 39. [12] In 2013, Phanuphak
et al. also reported high rates of anal HPV infection of all types in MSM in Bangkok, Thailand,
with frequencies among both HIV-positive (HIV+) of 85% and HIV-negative (HIV-) of 59%.
[10] The most common high-risk HPV types were 16, 51 and 58. [10] These and most other
similar studies were, however, in GM and/or BM subjects. [13–15] HPV types may also vary by
risk group, but little is known about HPV frequency in TGW. Prior Thai studies focused on
MSM in Bangkok or major tourist beach destinations such as Pattaya and Phuket. Equivalent
data in northern Thailand has not been published. Right now in Thailand, an HPV vaccine is
not included in the national immunization program either for boys or girls. Individuals who
want to receive this vaccine need to pay for the whole course by themselves. The cost for this
HPV vaccine in Thailand is around US $200–250 per person.
To provide a basis for future policymaking on the use of HPV vaccines in public immuniza-
tion programs for high-risk individuals, we studied the prevalence of anal HPV, its infecting
types, and risk factors for its acquisition among three subgroups of MSM in northern
Thailand.
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Methods
Study population and venue
The PIMAN Center is a clinic located in Chiang Mai city, northern Thailand, and has provided
voluntary counseling and testing and STI treatment services for MSM since 2007. The clinic is
operated by the Research Institute for Health Sciences (RIHES) of Chiang Mai University, and
participates in a range of multi-site epidemiological and clinical studies in MSM populations,
such as pre-exposure chemoprophylaxis for HIV prevention (e.g., the iPrEx trial) and rectal
microbicides (e.g., the MTN-017 study). About 400 MSM clients who attended the PIMAN
Center, between July 2012- January 2013, were approached about their interest in participating
in this HPV study. The study inclusion criteria were self-identification as GM, BM, or
TGW, age 18 years or older, and a history of anal receptive sexual intercourse in the preceding
6 months. Of those clients, there were 200 MSM who voluntarily provided informed consent to
be enrolled in the study.
Data and sample collection
Data were collected using a computer-assisted self-interview (CASI) program, and then by
trained study staff in a private room. Each participant was assigned a unique identification
code to anonymously link questionnaire responses and biologic specimens. Data collected via
CASI or by staff included socio-demographic characteristics, substance use history, gender
identity, history of HIV testing, history of prior STIs, and various sexual behaviors.
HIV testing
The HIV status of study participants who reported being HIV+ from testing elsewhere were
classified as such only if they provided written medical documentation of their status. Partici-
pants with undocumented, unknown, or prior HIV- status were provided with counseling and
HIV testing, if consenting, to HIV testing; those declining HIV testing were classified as HIV-
unknown (HIVunk).
HIV infection was determined by rapid test with the Alere Determine HIV 1/2 (Alere Medi-
cal Co, Ltd., Chiba, Japan), with confirmation of positives by enzyme-linked immunosorbent
assay with the AxSYM HIV 1/2 gO (ABBOTT, Wiesbaden, Germany). For discordant results
on these two tests, gelatin particle agglutination assay with the SERODIA—HIV (Fujirebio
Inc., Tokyo, Japan) was used for final determination.
Specimen collection
Anal samples for HPV DNA detection and genotyping were collected by physicians. A saline-
moistened nylon swab was introduced into the anal canal to 5 cm depth. The swab was rotated
in a circular motion for one minute, while gentle pressure was applied against the walls of the
anal canal. The swab sample was placed immediately in thinPrep PreserveCyt solution (Holo-
gic, Boxborough, MA, USA), and transported to the laboratory for cytology and HPV
DNA testing.
HPV detection and genotyping
DNA was extracted from the anal specimens using the DNeasy Blood & Tissue Kit (Qiagen,
Hilden, Germany). Briefly, the cells were preserved in PreserveCyt solution and were pelleted
by centrifugation at 1000 g at 20°C for 15 minutes. The cells were washed once with 1 x Dulbec-
co’s Phosphate-Buffered Saline (Invitrogen, Carlsbad, CA, USA), then subjected to DNA
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extraction according to the protocol provided by the manufacturer. The purified DNA was
stored at -20°C until use.
Nested polymerase chain reaction (PCR) assays determined the presence of HPV in the
10 μl DNA extracts from the anal specimens, using consensus PGMY09/11/HMB01 HPV L1
primers in the first-round. These were followed by the GP5+/6+ primers in the second-round.
[16] Co-amplification of the human β-globin gene in the first-round PCR was used as a positive
control; samples that were negative for both HPV DNA and β-globin were considered inade-
quate, whereas those negative for GP5+/6+ and positive for β-globin were regarded as HPV
DNA negative.
Samples that were positive for HPV using this approach were further analyzed using a line-
blot assay (LINEAR ARRAY HPV Genotyping Test [LA-HPV]; Roche Diagnostics GmBH, Mann-
heim, Germany), which detects 13 high-risk HPV genotypes (types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, and 68), and 24 low-risk genotypes (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67,
69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108). Positive and negative controls used for the
LA-HPV were those supplied with the kit. The probe for HPV type 52 is a mixed one that cross-
reacts with types 33, 35, and 58; thus, identifications of type 52 reported here include only those
without concurrent presence of the latter three types. Samples that tested positive by HPV DNA
PCR but without a positive band on the LA-HPV strip were classified as type undetermined.
Vaccine coverage
The HPV types identified were tabulated according to their coverage by the bivalent (16/18)
and quadrivalent (16/18/6/11) commercially available vaccines, as well as by the 7-valent (16/
18/31/33/45/52/58), and 9-valent (16/18/31/33/45/52/58/6/11) investigational ones. An HPV
+ participant was considered “covered” by a vaccine if1 of the type(s) identified to infect that
participant was among a vaccine’s component antigens. Thus, our estimates are for “partial”
coverage only, because a vaccine’s antigens may only correspond to some—but not all—of the
HPV infections in a participant co-infected with multiple types.
Statistical analysis
The data were analyzed statistically using Stata/IC for Windows, Version 10.0 (StataCorp LP,
College Station, TX, USA). Statistical significance for categorical data was determined by Pear-
son’s Chi-square test. Paired proportions were compared by McNemar's test. For bivariate
data, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated and statistical
significance determined by Chi-square (χ2) test.
Potential demographic, sexual, behavioral, and other risk factors or predictors for the as-
sessed outcome of HPV infection were analyzed by multivariate logistic regression. The vari-
able-selection process for the multivariate model began with bivariate analysis of each variable,
for which those with p values of<0.25 were candidates for the multivariate analysis. When spe-
cific analytical data cells had counts of zero, exact logistic regression was used. Forward selec-
tion was then applied by starting with a simple model and adding terms sequentially until
further additions did not significantly improve the fit. Covariates were removed from the
model if non-significant and not confounders. [17]
Ethics
Study protocols, questionnaires, and written informed consent were approved by the Ethics
Committee of the Research Institute for Health Sciences, Chiang Mai University. PIMAN Cen-
ter attendees were provided with information about the study and invited to participate. Only
those who voluntarily provided written informed consent were enrolled. Participants were
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informed of their study test results for HIV and HPV, followed by appropriate counseling and
treatment. Any STIs diagnosed in the course of the study were treated by the study team at the
PIMAN Center, and/or referred to appropriate clinical facilities elsewhere for further treat-
ment. Publication of the study data is in accordance with the community standards and ap-
proved by the ethics committee.
Results
Participant characteristics
The study population comprised equal numbers of GM (85, 42.5%) and TGW (85, 42.5%),
while 30 (15%) BM constituted the remainder (Table 1). GM were twice as likely to have any
university education (62%) than either BM (30%) or TGW (28%). The majority (55%) of the
participants was between 20 and 29 years old (overall age range 18–54 years) and 43% had a
university degree.
Sexual behavior and history
Five variables of sexual behavior stood out for statistically-significant differences between the
gender-identity groups (Table 2). TGW reported a higher frequency of exclusively receptive
anal sex than both the GM and BM (p< 0.001). GM reported less-frequent sexual intercourse
with men or women than the BM and TGW groups (p< 0.001). GM consumed alcohol before
sex less frequently than BM and TGW (p< 0.01). BM received something of value in exchange
Table 1. Demographic characteristics of age, education, occupation, and nationality, by gender-identity of MSM subjects in Chiang Mai, Thailand,
2012–2013.
Demographic Variables Gender identity Totals
Gay Men (GM) Bisexual Men (BM) Transgender Women (TGW) Statistic, p-value
(N = 85) (N = 30) (N = 85) (N = 200)
Age in years, N (%)
< 20 8 (9) 4 (13) 15 (18) 27 (14) χ2(6) = 12.6, p = 0.049
20–29 40 (47) 19 (63) 51 (60) 110 (55)
30–39 27 (32) 7 (23) 14 (16) 48 (24)
 40 10 (12) 0 5 (6) 15 (8)
Mean / Median 29.5 / 27 25.2 / 24 25.6 / 23 27.2 / 25
Min.-Max. 18–54 18–36 18–48 18–54
Highest education level, N(%)
None 3 (4) 4 (13) 5 (6) 12 (6) χ2(8) = 30.9, p = 0.000
Any primary (1 to 6 grades) 0 1 (3) 0 1 (1)
Any secondary (1 to 6 grades) 13 (15) 7 (23) 22 (26) 42 (21)
Any vocational (after 2° grade 3) 16 (19) 9 (30) 34 (40) 59 (30)
Any university 53 (62) 9 (30) 24 (28) 86 (43)
Main occupation, N(%)
Student 23 (27) 5 (17) 32 (38) 60 (30) χ2(4) = 15.8, p = 0.003
Employed 58 (68) 17 (57) 43 (51) 118 (59)
Unemployed 4 (5) 8 (27) 10 (12) 22 (11)
Nationality, N(%)
Thai 84 (99) 29 (97) 85 (100) 198 (99) χ2(2) = 2.5, p = 0.280, NS
Thai ethnic minority 1 (1) 1 (3) 0 2 (1)
doi:10.1371/journal.pone.0124499.t001
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Table 2. Frequency of sexual and other behaviors, by gender-identity of MSM subjects in Chiang Mai, Thailand, 2012–2013.








(N = 85) (N = 30) (N = 85) (N = 200)
Regular partner status, N(%) χ2(2) = 3.4,
p = 0.187, NS
No 61 (72) 26 (87) 68 (80) 155 (78)
Yes 24 (28) 4 (13) 17 (20) 45 (22)
Sexual role, N(%) χ2(4) = 69.0,
p = 0.000
Insertive only 0 3 (10) 1 (1) 4 (2)
Receptive only 40 (47) 5 (17) 76 (89) 121 (60)
Both insertive and receptive 45 (53) 22 (73) 8 (9) 75 (38)
Last 6 months, anal intercourse with sex partner(s), N
(%)
None 1 (1) 0 2 (2) 3 (2) χ2(6) = 4.8,
p = 0.310, NS
Yes 78 (95) 24 (89) 80 (95) 182 (94)
No sex at all 3 (4) 3 (11) 2 (2) 8 (4)
Declined to answer * 3 3 1 7
If yes, use condom all the time last 6 months χ2(2) = 4.5,
p = 0.107, NS
Yes 38 (49) 7 (29) 28 (35) 73 (40)
No 40 (51) 17 (71) 52 (65) 109 (60)
Sexual intercourse frequency with men or women, N(%) χ2(6) = 26.9,
p = 0.000
Everyday 0 4 (13) 8 (9) 12 (6)
3–4 times per week 12 (14) 12 (40) 23 (27) 47 (24)
1–2 times per week 27 (32) 6 (20) 30 (35) 63 (32)
One per month or less 46 (54) 8 (27) 24 (28) 78 (39)
Drink alcohol before sex with BM, GM, or TGW, N(%) χ2(6) = 17.8,
p = 0.007
Every time 1 (1) 6 (20) 5 (6) 12 (6)
Almost every time 8 (9) 4 (13) 13 (15) 25 (12)
Sometimes 45 (53) 13 (43) 47 (55) 105 (52)
Never 31 (36) 7 (23) 20 (24) 58 (29)
Ever give money, gifts or valuables in exchange for sex
with BM, GM or TGW, N(%)
χ2(2) = 2.9,
p = 0.238, NS
No 62 (73) 24 (80) 71 (84) 157 (78)
Yes 23 (27) 6 (20) 14 (16) 43 (22)
If yes, when was the last time χ2(2) = 2.1,
p = 0.354, NS
1 year or less 17 (74) 5 (83) 13 (93) 35 (81)
More than 1 year 6 (26) 1 (17) 1 (7) 8 (19)




Never 71 (84) 12 (40) 60 (71) 143 (72)
Ever 14 (16) 18 (60) 25 (29) 57 (28)
If ever last time χ2(2) = 0.9,
p = 0.642, NS
1 year or less 10 (71) 15 (83) 18 (72) 43 (75)
(Continued)
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for sex more often than GM or TGW (p< 0.0001). TGW reported lower frequency than GM
and BM of penile symptoms suggestive of STIs (p<0.001).
HIV and HPV prevalence and co-infections
Of the 200 participants, 49 (24.5%) were HIV+, 122 (61.0%) HIV-, and 29 (14.5%) HIVunk
(Table 3). HPV infection with any type was found in 157 (79.7%) of 197 with adequate anal-
swab samples. Among the HIV+ subjects, all 48 (100%) with adequate specimens were found
on Linear Array HPV assay to be infected with one or more HPV types, which was significantly
higher than the 70% rate (84 of 120) among HIV- subjects (p<0.01).
Infection with multiple HPV types was common (Table 3): 13% (25/197) were co-infected
with two types, 32% (64) 3-to-5 types, 17% (37) 6-to-8 different types, and 3% (6)9 types.
The mean number of HPV types was 4.8 among HIV+ participants (range 1 to 12), compared
to 3.4 (range 1–10) in the HIV- (p< 0.001)
HPV infection with any of the 13 high-risk types was found in 132 of 197 (67.0%) (Table 3).
Co-infections with1 high-risk types among HIV+ was 94% (45 of 48), and in HIV- 54% (65
of 120) (p< 0.0001).
Table 2. (Continued)








(N = 85) (N = 30) (N = 85) (N = 200)
More than 1 year 4 (29) 3 (17) 7 (28) 14 (25)
Ever circumcised?, N(%) χ2(2) = 0.7,
p = 0.705, NS
Yes 4 (5) 1 (3) 2 (2) 7 (4)
No 81 (95) 29 (97) 83 (98) 193 (96)
Number of total sex partner(s) last 6 months, N(%) χ2(6) = 11.0,
p = 0.088, NS
None 3 (4) 3 (11) 2 (2) 8 (4)
1 20 (24) 3 (11) 19 (23) 42 (22)
2–4 34 (41) 6 (22) 31 (37) 71 (37)
5 or more 25 (30) 15 (56) 32 (38) 72 (37)
Declined to answer * 3 3 1 7
Mean / Median 4.6 / 3 14.2 / 7 10.8 / 3.5 8.6 / 3
Min.-Max. 0–45 0–103 0–300 0–300
Ever have unusual fluid, urinary irritation, ulcer, or rash
on penis in last 6 months, N(%)
χ2(2) = 16.1,
p = 0.000
Yes 17 (20) 9 (30) 3 (4) 29 (14)
No 68 (80) 21 (70) 82 (96) 171 (86)
If yes, see doctor and get diagnosis χ2(2) = 1.4, p = >
0.507, NS
Yes 9 (53) 3 (33) 2 (67) 14 (48)
No 8 (47) 6 (67) 1 (33) 15 (52)
* Not included in testing for statistical significance.
doi:10.1371/journal.pone.0124499.t002
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HPV types and vaccine coverage
The most common high-risk HPV types were 16 (27%), 58 (23%), 51(18%), and 39 (14%)
(Fig 1). Infection by type 16 was more common in HIV+ (40%, 19/48), versus 22% (26/120) in
HIV- (p< 0.02). Increasing vaccine valences from 2, to 4, to 7, and to 9 increased the percent-
age of participants who were infected with at least one HPV type covered in a vaccine from
35.5% (70/197), to 48.2% (95), to 56.4% (111), and to 64.0% (126), respectively (Table 4). HPV
vaccine coverage for either HIV+ or HIV- increased steadily as valency increased from 2 to 4,
to 7, and to 9 (Table 5).
Table 3. HPV infections and co-infections by HIV infection status of MSM subjects studied in Chiang Mai, Thailand, 2012–2013.
Variables HIV Infection Totals
HIV+ HIV- HIVunk* Statistic, p-value
(N = 49) (N = 122) (N = 29) (N = 200)
HPV DNA by PCR, N(%) χ2(1) = 12.3, p = 0.000
HPV+ 48 (100) 94 (78) 25 (86) 167 (85)
HPV- 0 26 (22) 4 (14) 30 (15)
Inadequate specimen* 1 2 0 3
HPV DNA by linear array, N(%) χ2(1) = 15.0, p = 0.000
HPV+ 48 (100) 84 (74) 25 (86) 157 (83)
HPV- 0 29 (26) 4 (14) 33 (17)
Undetermined type, Not specified* 0 7 0 7
Number HPV co-infection, N(%) χ2(5) = 32.2, p = 0.000
None 0 36 (30) 4 (14) 40 (20)
1 2 (4) 20 (17) 6 (21) 28 (14)
2 5 (10) 15 (12) 5 (17) 25 (13)
3–5 25 (52) 34 (28) 5 (17) 64 (32)
6–8 14 (29) 13 (11) 7 (24) 34 (17)
 9 2 (4) 2 (2) 2 (7) 6 (3)
Mean / Median 4.8 / 4 3.4 / 3 4.1 / 3 3.9 / 4
Min.-Max. 1–12 1–10 1–9 1–12
Frequency of low and high risk HPV types, N(%) χ2(3) = 25.0, p = 0.000
None 0 36 (30) 4 (14) 40 (20)
Only low risk(LR) type(s) 3 (6) 19 (16) 3 (10) 25 (13)
Only high risk(HR) type(s) 5 (10) 8 (7) 4 (14) 17 (9)
Both LR and HR type(s) 40 (83) 57 (48) 18 (62) 115 (58)
Number of high-risk HPV co-infection(s), N(%) χ2(4) = 28.8, p = 0.000
None 3 (6) 55 (46) 7 (24) 65 (33)
1 11 (23) 20 (17) 12 (41) 43 (22)
2 12 (25) 22 (18) 1 (3) 35 (18)
3–5 18 (38) 22 (18) 8 (28) 48 (24)
6–8 4 (8) 1 (1) 1 (3) 6 (3)
Mean / Median 2.8 / 2 2.2 / 2 2.2 / 1 2.4 / 2
Min.-Max. 1–7 1–7 1–6 1–7
* Not included in testing for statistical significance.
doi:10.1371/journal.pone.0124499.t003
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Determinants of anal HPV infection
On univariate analysis, the odds ratio (OR) for anal HPV infection with any type virus among
GM was 9.0 (95% CI 2.97–28.03, p<0.001), and among TGW 4.5 (95% CI 1.63–12.26,
p = 0.001), compared to BM as the referents (Table 6). The adjusted odd ratio (AOR) by exact
logistic regression for GM was 5.3 (95% CI 1.2–25.7, p = 0.027), compared to BM as referents.
For HIV+ participants, the any-type bivariate OR was 41.9 (95% CI 2.54–698.02, p = 0.001),
compared to the HIV- as the referent. The AOR for the HIV+ was 20.29 (95% CI 3.28-1,
p< 0.001), compared to the HIV-.
Infection with any of the 13 high-risk HPV subtypes showed a bivariate OR of 5.4 for GM
(95% CI 2.01–15.03, p<0.001) and 4.67 for TGW (95% CI 1.74–12.85, p<0.001), compared to
BM referents. The multivariate AOR for GM was 4.2 (95% CI 1.2–14.6, p = 0.021) and for
TGW was 6.2 (95% CI 1.8–20.9, p = 0.003), compared to BM (Table 7).
For high-risk HPV subtypes, the HIV+ORwas 12.7 (95%CI 3.7–66.5, p< 0.001) compared to
HIV-. The high-risk AOR for HIV+ was 12.8 (95% CI 3.6–45.8, p< 0.0001), compared to HIV-.
Discussion
Our study showed an overall high prevalence of anal HPV infection with any of the 37 virus
types assayed among northern Thai MSM who identified themselves as GM, BM, and TGW;
Fig 1. Prevalence of high-risk HPV types, by HIV status, ranked from left to right by decreasing percentage among total participants.
doi:10.1371/journal.pone.0124499.g001
Anal HPV Infection and Genotype Diversity in MSM
PLOSONE | DOI:10.1371/journal.pone.0124499 May 1, 2015 9 / 17
and those who were HIV+ were 100% infected with HPV, significantly higher than those who
were HIV- where the rate was 70%. This prevalence was higher than the 85% for HIV+ and
58.5% for HIV- MSM found in Bangkok in Central Thailand (nearly all were GM or BM), [10]
as well as ever reported in other countries such as Brazil (65.6% for HIV+), [13] Taiwan (74.2%
for HIV+), [14] and China (62–82% for HIV+, 58% for HIV-). [12,15]
For the 13 HPV subtypes considered high risk for disease sequelae, our infection prevalence
was also higher among HIV+ and HIV- participants (94% and 54%, respectively), compared to
HIV+ and HIV- MSM from Bangkok, 56.5% and 36.6%, respectively [10] (this prior study re-
ported overall MSM rates). Our most common high risk subtype found in HIV+ MSM was
HPV16 followed by 58, 51, and 39, findings quite similar to Bangkok MSM, where the most
Table 4. Coverage by commerciala,b and investigationalc,d HPV vaccines of1 HPV infecting type(s), by gender identity of MSM subjects in
Chiang Mai, Thailand, 2012–2013.
No. of participant / Total
cases (%)






2-valent 33 / 85 (38.8) Ref.
4-valent 45 / 85 (52.9) +14.1 (5.5–22.7) 1.4 (1.1–1.6) χ2(1) = 12.0,
p = 0.0005
7-valent 54 / 85 (63.5) +24.7 (14.4–35.1) 1.6 (1.3–2.0) χ2(1) = 21.0,
p = 0.000
9-valent 61 / 85 (71.8) +32.9 (21.8–44.1) 1.9 (1.5–2.3) χ2(1) = 28.0,
p = 0.000
Bisexual Men, N(%)
2-valent 7 / 29 (24.1) Ref.
4-valent 10 / 29 (34.5) +10.3 (-4.2–24.9) 1.4 (1.0–2.1) χ2(1) = 3.0,
p = 0.083, NS
7-valent 8 / 29 (27.6) +3.5 (-6.6–13.5) 1.1 (0.9–1.5) χ2(1) = 1.0,
p = 0.317, NS
9-valent 11 / 29 (37.9) +13.8 (-2.2–29.8) 1.6 (1.0–2.5) χ2(1) = 4.0, p = 0.046
Transgender Women,
N(%)
2-valent 30 / 83 (36.1) Ref.
4-valent 40 / 83 (48.2) +12.1 (3.8–20.3) 1.3 (1.1–1.6) χ2(1) = 10.0,
p = 0.002
7-valent 49 / 83 (59.0) +22.9 (12.7–33.1) 1.6 (1.3–2.0) χ2(1) = 19.0,
p = 0.000
9-valent 54 / 83 (65.1) +28.9 (18.0–39.9) 1.8 (1.4–2.3) χ2(1) = 24.0,
p = 0.000
All participant, N(%)
2-valent 70 / 197 (35.5) Ref.
4-valent 95 / 197 (48.2) +12.7 (7.5–17.8) 1.4 (1.2–1.5) χ2(1) = 25.0,
p = 0.000
7-valent 111 / 197 (56.4) +20.8 (14.6–27.0) 1.6 (1.4–1.8) χ2(1) = 41.0,
p = 0.000
9-valent 126 / 197 (64.0) +28.4 (21.6–35.2) 1.8 (1.5–2.1) χ2(1) = 56.0,
p = 0.000
a 2–valent coverage: number infected with 1 HPV type(s) 16 and/or 18
b 4–valent coverage: number infected with 1 HPV type(s) 16, 18, 6, and/or 11
c 7–valent coverage: number infected with 1 HPV type(s) 16, 18, 31, 33, 45, 52, and/or 58
d 9–valent coverage: number infected with 1 HPV type(s) 16, 18, 31, 33, 45, 52, 58, 6, and/or 58).
doi:10.1371/journal.pone.0124499.t004
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common of all subtypes were HPV16 (22.5%), 68 (13.3%), 58 (10.8%), 51 (10.8%) and 39
(10%). [10] Our prevalence of high-risk HPV was also higher than reported from Brazil (40.7%
for HIV+), [13] Taiwan (40.4% for HIV+), [14] and China (61% for HIV+, 40% for HIV-).
[15]
Self-reported gender identity of GM and TGWwas independently associated with prevalent
HPV infection, when compared with BM, particularly for infection with high-risk HPV types.
The prevalence was highest in those who self-identified as GM (74%) and TGW (71%) com-
pared with those who self-identified as BM (35%). Others in Thailand and elsewhere described
the prevalence of HPV infection in MSM, [10–15, 18, 19] but did not examine HPV epidemiol-
ogy in gender-identity subpopulations that differ in sexual behavior practices. In particular,
TGW were absent from published studies in Thai MSM. [18] We are unaware of others
Table 5. Coverage by commerciala,b and investigationalc,d HPV vaccines of1 HPV infecting type(s), by HIV status of MSM subjects in Chiang
Mai, Thailand, 2012–2013.
No. of participant / Total
cases (%)






2-valent 28 / 48 (58.3) Ref.
4-valent 34 / 48 (70.8) +12.5 (1.1–23.9) 1.2 (1.0–1.4) χ2(1) = 6.0, p = 0.014
7-valent 39 / 48 (81.3) +22.9 (8.9–36.9) 1.4 (1.1–1.7) χ2(1) = 11.0,
p = 0.001
9-valent 42 / 48 (87.5) +29.2 (14.2–44.1) 1.5 (1.2–1.9) χ2(1) = 14.0,
p = 0.0002
HIV-, N(%)
2-valent 32 / 120 (26.7) Ref.
4-valent 47 / 120 (39.2) +12.5 (5.8–19.3) 1.5 (1.2–1.8) χ2(1) = 15.0
p = 0.0001
7-valent 55 / 120 (45.8) +19.2 (11.3–27.0) 1.7 (1.4–2.2) χ2(1) = 23.0,
p = 0.000
9-valent 65 / 120 (54.2) +27.5 (18.7–36.3) 2.0 (1.6–2.6) χ2(1) = 33.0,
p = 0.000
HIV unk, N(%)
2-valent 10 / 29 (34.5) Ref.
4-valent 14 / 29 (48.3) +13.8 (-2.2–29.8) 1.4 (1.1–2.0) χ2(1) = 4.0, p = 0.046
7-valent 17 / 29 (58.6) +24.1 (5.1–43.2) 1.7 (1.1–2.5) χ2(1) = 7.0,
p = 0.008




2-valent 70 / 197 (35.5) Ref.
4-valent 95 / 197 (48.2) +12.7 (7.5–17.8) 1.4 (1.2–1.5) χ2(1) = 25.0,
p = 0.000
7-valent 111 / 197 (56.4) +20.8 (14.6–27.0) 1.6 (1.4–1.8) χ2(1) = 41.0,
p = 0.000
9-valent 126 / 197 (64.0) +28.4 (21.6–35.2) 1.8 (1.5–2.1) χ2(1) = 56.0,
p = 0.000
a 2–valent coverage: number infected with 1 HPV type(s) 16 and/or 18
b 4–valent coverage: number infected with 1 HPV type(s) 16, 18, 6, and/or 11
c 7–valent coverage: number infected with 1 HPV type(s) 16, 18, 31, 33, 45, 52, and/or 58
d 9–valent coverage: number infected with 1 HPV type(s) 16, 18, 31, 33, 45, 52, 58, 6, and/or 58.
doi:10.1371/journal.pone.0124499.t005
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Table 6. Crude and adjusted Odds ratios by bivariate and exact logistic regression for any HPV positivity by demographic, behavioral, and sexual
risk factors of MSM in Chiang Mai, Thailand.
Characteristics No.
cases




OR 95% CI p-value AOR b 95% CI p-value
Gender identity
Bisexual men 29 14 (48) Ref. Ref.
Gay men 85 76 (89) 9.0 3.0–28.0 0.000 5.3 1.2–
25.7
0.027




Negative 120 84 (70) Ref. Ref.
Positive 48 48 (100) 41.9 2.5–
698.0
0.001 20.3 3.3 -
+inf.
0.0002




< 20 27 22 (82) Ref.
20–29 108 84 (78) 0.8 0.2–2.5 0.675
30–39 47 37 (79) 0.8 0.2–3.2 0.776




Insertive only & both 78 58 (74) Ref.
Receptive only 119 99 (83) 1.7 0.8–3.6 0.132
Ever used hormones
Never 98 76 (78) Ref.
Ever 99 81 (82) 1.3 0.6–2.8 0.457
Alcohol consumption
Never 18 15 (83) Ref.
Ever 179 142 (79) 0.8 0.1–2.9 0.687
Frequency of sexual intercourse with BM, GM or TGM
1–2 times/week or less 140 111 (79) Ref.
3–4 times/week or more 57 46 (81) 1.1 0.5–2.6 0.823
Drank alcohol before having sex with BM, GM or TGW
Never / sometime 162 135 (83) Ref. Ref.
Almost every time / Every time 35 22 (63) 0.3 0.1–0.8 0.006 0.4 0.1–1.3 0.127
BM, GM or TGW partner drank alcohol before having sex with
you
Never / sometime 164 134 (82) Ref.
Almost every time/ Every time 33 23 (70) 0.5 0.2–1.4 0.118
Ever received money, gifts or valuables in exchange for sex
Never 141 114 (81) Ref.
Ever 56 43 (77) 0.8 0.4–1.8 0.522
Ever had any fluid, irritating urinary symptom, ulcer, or rash
on your penis
No 169 135 (80) Ref.
Yes 28 22 (79) 0.9 0.3–3.0 0.873
Total sex partner(s) last 6 months
(Continued)
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reporting our high overall and high-risk type HPV rates in TGW. Our study identified and
confirmed previous findings that HIV+ is a stronger risk factor for overall and high-risk HPV
infections than HIV- and HIVunk status. [12]
The difference of vaccine coverage and ratio (above 2-valent) of the 9-valent HPV vaccine
of any HIV statuses or gendered groups were higher than other vaccines. Although the
2-valent, 4-valent, and 7-valent HPV vaccines had lower coverage than the 9-valent, as would
be expected, nevertheless these lesser-valent vaccines still had high coverage in the subjects
we studied.
For HIV- participants, unprotected receptive anal intercourse was not associated with HPV,
as was reported from Italy, [19] while, in contrast, this was significantly associated with HPV
infection in China. [15] Our lack of multivariate association of HPV with increased numbers of
sex partners differed from data in Italy in which both lifetime and recent numbers of sexual
partners were significantly associated with anal HPV infection. [19] Drinking alcohol before
sex also lacked any multivariate association among our participants. In contrast, the HIM
study in São Paulo (Brazil), Cuernavaca (Mexico), and Tampa (USA) demonstrated alcoholic








OR 95% CI p-value AOR b 95% CI p-value
0–1 49 35 (71) Ref. Ref.
2 or more 141 117 (83) 2.0 0.8–4.4 0.082 2.2 0.8–6.0 0.157
Number of female sex partner(s) last 6 months
0–1 172 143 (83) Ref. Ref.
2 or more 16 7 (44) 0.2 0–0.5 0.000 0.3 0.0–2.4 0.368
Use condom all the time last 6 months with sex partner(s)
No sex partner / No anal sex 10 7 (70) Ref.
Yes 73 60 (82) 2.0 0.3–10.1 0.359
No 107 85 (79) 1.7 0.2–8.0 0.486
Use condom all the time last 6 months with regular sex
partner(s)
No sex partner / No anal sex 74 56 (76) Ref.
Yes 46 38 (83) 1.5 0.6–4.5 0.370
No 73 59 (81) 1.4 0.6–3.2 0.450
Use condom all the time last 6 months with casual sex
partner(s)
No sex partner / No anal sex 47 36 (77) Ref.
Yes 75 61 (81) 1.3 0.5–3.5 0.528
No 72 59 (82) 1.4 0.5–3.8 0.477
a Exact logistic regression used for these estimates due to zero cell counts
b AOR = adjusted odd ratio. All measures adjusted for drinking alcohol before having sex, number of total sex partner(s) in last 6 months and number of
female sex partner(s) in last 6 months
OR = crude odds ratio
Inf. = infinity
Ref. = Reference value.
doi:10.1371/journal.pone.0124499.t006
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Table 7. Crude and adjusted odds ratios by bivariate and logistic regression, for high-risk-type HPV positivity, by demographic, behavioral, and
sexual risk factors of MSM in Chiang Mai, Thailand.
Characteristics No.
cases




OR 95% CI p-value AOR a 95% CI p-value
Gender identity
Bisexual men 29 10 (35) Ref. Ref.











Negative 120 65 (54) Ref. Ref.





Unknown 29 22 (76) 2.7 1.0–7.9 0.033 3.1 1.1–8.6 0.033
Age in years
< 20 27 20 (74) Ref.
20–29 108 67 (62) 0.6 0.2–1.6 0.243
30–39 47 32 (68) 0.8 0.2–2.4 0.587




Insertive only & both 78 47 (60) Ref.
Receptive only 119 85 (71) 1.6 0.9–3.2 0.103
Ever used hormones
Never 98 61 (62) Ref.
Ever 99 71 (72) 1.5 0.8–2.9 0.157
Alcohol consumption
Never 18 14 (78) Ref.
Ever 179 118 (66) 0.6 0.1–1.9 0.308
Frequency of sexual intercourse with BM, GM or TGM
1–2 times/week or less 140 96 (69) Ref.
3–4 times/week or more 57 36 (63) 0.8 0.4–1.6 0.464
Drank alcohol before having sex with BM, GM or TGW
Never / sometime 162 113 (70) Ref. Ref.
Almost every time / Every time 35 19 (54) 0.5 0.2–1.2 0.078 0.6 0.2–1.4 0.223
Your BM, GM or TGW partner drank alcohol before having
sex with you
Never / sometime 164 111 (68) Ref.
Almost every time / Every time 33 21 (64) 0.8 0.4–2.0 0.652
Ever received money, gifts or valuables in exchange for
sex
Never 141 99 (70) Ref.
Ever 56 33 (59) 0.6 0.3–1.2 0.129
Ever had any fluid, irritating urinary symptom, ulcer, or
rash on your penis
No 169 111 (66) Ref.
Yes 28 21 (75) 1.6 0.6–4.6 0.331
Total sex partner(s) last 6 months
(Continued)
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Our study had several advantages in studying anal HPV prevalence, including a large num-
ber of MSM who identify themselves specifically as GM, BM, and TGW. Little is known about
HPV infection in TGW and its risk factors. Computer-assisted interviewing with CASI (see
methods) may have reduced response bias as homosexual sex is still stigmatized in Thailand.
There were a number of limitations. The cross-sectional design did not allow evaluation of
HPV incidence, causation, and progression, and may have been affected by confounding. The
number of participants with and without confirmed HIV infection was small because of the un-
known HIV status of many participants, which limited statistical sub-analyses. The limited
number of HIV+ participants precluded evaluation of CD4 count and antiretroviral drug use,
which have been found to be significantly associated with HPV infection in some studies. [22,
23] Our findings of vaccine coverage were only “partial”, based on infection with one or more
HPV types included in commercial and investigational vaccines. An analysis of “full” coverage
of vaccines that would have prevented all the subtypes in patients infected with multiple types
would have resulted in far lower coverage rates.
Our findings of HPV prevalence and vaccine coverage indicate that MSM in northern Thai-
land would benefit by protection from the serious consequences of HPV infection resulting
from use of any of the HPV vaccines, with increasing protection as valences increases from 2 to
4 among commercial products, and from 7 to 9 among investigational ones. Further studies
with follow-up of these and new consenting participants could evaluate in larger numbers the








OR 95% CI p-value AOR a 95% CI p-value
0–1 49 30 (61) Ref.
2 or more 141 97 (69) 1.4 0.7–2.9 0.332
Number of female sex partner(s) last 6 months
0–1 172 120 (70) Ref. Ref.
2 or more 16 6 (38) 0.3 0.1–0.8 0.009 0.8 0.2–3.7 0.798
Use condom all the time last 6 months with sex partner(s)
No sex partner / No anal sex 10 6 (60) Ref.
Yes 73 52 (71) 1.6 0.3–7.8 0.468
No 107 69 (65) 1.2 0.2–5.5 0.777
Use condom all the time last 6 months with regular sex
partner(s)
No sex partner / No anal sex 74 52 (70) Ref.
Yes 46 30 (65) 0.8 0.3–1.9 0.563
No 73 46 (63) 0.7 0.3–1.5 0.351
Use condom all the time last 6 months with casual sex
partner(s)
No sex partner / No anal sex 47 29 (62) Ref.
Yes 75 55 (73) 1.7 0.7–4.0 0.177
No 72 47 (65) 1.2 0.5–2.7 0.691
a AOR = adjusted odd ratio. All measures adjusted for drinking alcohol before having sex and number of female sex partner(s) in last 6 months
OR = crude odds ratio
Ref. = Reference value.
doi:10.1371/journal.pone.0124499.t007
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